Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
Analysts Estimate Corcept Therapeutics (CORT) to Report a Decline in Earnings: What to Look Out for
11:07am, Wednesday, 22'nd Oct 2025
Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer
12:35pm, Wednesday, 15'th Oct 2025
Corcept files a marketing application with the EMA for relacorilant in platinum-resistant ovarian cancer after studies show survival gains.
Corcept Transition To New Specialty Pharmacy Well Underway
09:13am, Wednesday, 15'th Oct 2025
Corcept Therapeutics (CORT) has added Curant Rare as a second specialty pharmacy to handle increased prescription demand for Korlym. Optime Care will discontinue servicing CORT prescriptions due to it
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym?
11:41am, Wednesday, 01'st Oct 2025
Corcept expects relacorilant to ease sole reliance on Korlym for revenues. Relacorilant is under FDA review for Cushing's syndrome and ovarian cancer.
Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics
09:00am, Wednesday, 01'st Oct 2025
ATLANTA--(BUSINESS WIRE)--Curant Health is proud to announce that Curant Rare has been selected by Corcept Therapeutics as a specialty pharmacy to provide personalized care, coordinated access to ther
Corcept Primed For An Upside EPS Surprise
12:06pm, Friday, 26'th Sep 2025
My September quarter EPS forecast of $0.29 for Corcept could meaningfully beat analyst projections of $0.17. Approval of the company's Relacorilant medication by the FDA will essentially resolve any g
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer
01:01pm, Thursday, 11'th Sep 2025
CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.
FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
08:00am, Wednesday, 10'th Sep 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
Can Korlym Drive Corcept's Growth Through the Rest of 2025?
11:00am, Tuesday, 02'nd Sep 2025
CORT projects $850-$900M in 2025 revenues as Korlym sales rise and relacorilant nears an FDA decision for Cushing's syndrome.
Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?
03:06pm, Monday, 25'th Aug 2025
CORT's stock is up 39.6% year to date as relacorilant nears FDA approval for Cushing's syndrome and expands into cancer studies.
Corcept's Q2 Demand Grows 60%, Penetrating Large Type 2 Diabetes Market Early
09:54pm, Thursday, 07'th Aug 2025
Corcept's Q2 2025 results were impacted by specialty pharmacy bottlenecks and discounting, masking robust underlying 60% growth in demand for its therapies. Revenue guidance was trimmed on fulfillment
Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript
02:32pm, Friday, 01'st Aug 2025
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q2 2025 Earnings Call July 31, 2025 5:00 PM ET Company Participants Atabak Mokari - CFO & Treasurer Gary Charles Robb - Chief Business Officer & Secret
